ClinicalTrials.gg
RecruitingNCT06897553Updated Mar 27, 2025

ACT for Mental Health in Neurological Disorders

An interventional study of ACT-based group therapy in Neurological Disorders, Mental Health and Executive Function (Cognition), sponsored by Bielefeld University. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.

Primary conditionBrain InjuriesRegistry: Nervous System DiseasesReclassifiedWhy we changed it
Registry
Nervous System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Injuries
Why
  1. The study's listed conditions name Brain Injuries, a narrower term within Nervous System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bielefeld University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2024, registered Mar 2025).
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Brain Injuries with a site in Germany — 5 open to participants now, 5 under way, none of them phase 3. Brain Injuries · Germany.

Started
2024
the only one that year
No phase
7 of 20
1 open now
Registered
18th of 20
by date
Lead sponsor
1 of 20
Bielefeld University

Among the 20 studies in Brain Injuries with a site in Germany, this one is the only one that started in 2024, is one of 7 with no phase, and was the 18th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

5 of the 20 studies in Brain Injuries with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Brain Injuries with a site in Germany, or all of them as a file.
02

Study summary

The goal of this clinical trial is to examine the efficacy of this manual for mental health in people with mixed neurological disorders, including post-COVID. These conditions are often associated with cognitive impairment, which may hamper the effects of psychoterapy. Executive functioning and especially the ability to abstract thinking may be useful for individuals using Acceptance and Commitment Therapy. Therefore, the main questions research questions are:

  • Is this intervention effective in improving mental health?
  • Do executive functions predict the extent of social participation and mental health at the end of therapy? Participants will take part in 8 weekly group therapy sessions of 100 minutes each.
Read the detailed description

Mental health issues, especially depression, anxiety, and stress, are common in people with neurological disorders and post-COVID but often neglected and hence, remain untreated. Acceptance and Commitment Therapy (ACT) is a promising approach to assist people in adapting to their conditions by improving "psychological flexibility".

A previous study translated an adapted group psychotherapy manual for stroke survivors into German and demonstrated its feasibility. This pilot study also gave first indications on the manual's efficacy in reducing symptoms of anxiety, depression, and stress. The aim of this study is to investigate the efficacy of this ACT-based group therapy. People with neurological disorders may have impairments in executive functions, which can affect the psychotherapeutic process. Since ACT often uses metaphors and imagery, executive functions, particularly the ability to abstract, could influence the efficacy of the therapy and are therefore being investigated in this study. The program includes 8 weekly sessions with a session length of 100 minutes.

03

Conditions studied

  • Neurological Disorders
  • Mental Health
  • Executive Function (Cognition)
  • Depression/Anxiety
  • Stress
  • Brain Injury
  • Post-COVID

Keywords

  • Acceptance and Commitment Therapy (ACT)
  • group therapy
  • neurological disorders
  • brain injury
  • anxiety
  • stress
  • depression
  • executive functioning
  • abstraction ability
  • Post-COVID
04

In context

Brain Injuries Reclassified

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

This study's planned enrollment of 44 is close to the median of 41 across 613 interventional studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Bielefeld University is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Compared within Brain Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Value above a cut-off of the DASS-21 subscales (depression > 10, anxiety > 6, and stress > 10)
  • Sufficient cognition and language ability (clinical rating)
  • Sufficient therapy motivation (clinical rating)

Exclusion criteria

Exclusion Criteria:

  • Behavioral disorders (e.g., high irritability or apathy in clinical rating)
  • Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability)
  • Simultaneous psychotherapy or neuropsychological therapy
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Waiting List and ACT group therapy

    Eight weeks of waiting list are followed by eight weeks of ACT group therapy, see study design.

    Behavioral: ACT-based group therapy

Interventions

  • BehavioralACT-based group therapy

    ACT-based group therapy based on the manual "Living Well with Neurological Conditions" published by Hill et al. (2017; NHS Fundation Trust; available: https://goo.gl/aX6qB5). The manual was translated into German and adapted by shortening sessions, simplifying language and adapting exercises based on clinical experience. The publication of the feasibility study for the adapted manual is currently in preparation. The group therapy includes eight weekly sessions with a duration of 100 minutes each. Three to six individuals participate in a group. The therapy is delivered by at least one licensed psychotherapists. A co-therapist might be included based on individual needs of the group members.

07

What researchers measure

Primary outcomes

  1. Depression and Anxiety Stress Scales-21 (Lovibond, 1995)

    Measure of psychological burden to investigate efficacy. Scores range from 0 to 63 with higher values indicating higher burden.

    Time frame: Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart)

  2. Acceptance and Action Questionnaire-Acquired Brain Injury (Sylvester, 2011)

    Measure of psychological flexibility to investigate efficacy. Scores range from 0 to 36 with higher values indicating higher inflexibility.

    Time frame: Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart)

  3. Wechsler Adult Intelligence Scale - Fourth Edition (Similarities subtest; Wechsler, 2008)

    Measure of individual's ability to recognize and articulate the commonalities between different objects, reflecting their abstraction ability. This will be used to examine the influence of the ability of abstract thinking. Scores range from 0 to 36 with higher values indicating higher ability of abstraction.

    Time frame: pre- and post-intervention (pre and post are presumably 8 weeks apart)

Secondary outcomes

  1. Patient Health Questionnaire-9 (Kroenke, 2001)

    Measure of depressive symptoms to investigate efficacy. Scores range from 0 to 27 with higher values indicating more severe depressive symptoms.

    Time frame: Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart)

  2. Generalized Anxiety Disorder Scale-7 (GAD-7; Spitzer et al., 2007)

    Measure of anxiety symptoms to investigate efficacy. Scores range from 0 to 21 with higher scores indicating higher anxiety.

    Time frame: Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart)

  3. Valuing Questionnaire (Smout, 2014)

    Measure of valued living to investigate efficacy. Scores range from 0 to 60 with higher values indicating higher value-congruent living.

    Time frame: Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart)

  4. Self-as-context scale (Zettle, 2018)

    Measure of self as context to investigate efficacy. Scores range from 10 to 70 with higher values indicating a perspective closer to self-as-context.

    Time frame: Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart)

  5. World Health Organization Disability Assessment Schedule 2.0 (V.S. Üstün, 2010; Plain German)

    Measure of functional impairments and disabilities.

    Time frame: Before waiting list condition; and pre- and post-intervention (pre and post are presumably 8 weeks apart)

  6. Regensburg Word Fluency Test (Aschenbrenner, 2001)

    Measure of verbal fluency.

    Time frame: pre- and post-intervention (pre and post are presumably 8 weeks apart)

  7. Stroop Test in Vienna Test System (Müller & Ziegler, 2001)

    Measure of cognitive flexibility and inhibition of irrelevant stimuli.

    Time frame: pre- and post-intervention (pre and post are presumably 8 weeks apart)

Other outcomes

  1. Group therapy session questionnaire (Zoubek, 2013; Plain German)

    Measure of treatment acceptance and satisfaction for patients regarding each session (GTS-P Session), for patients regarding the entire therapy (GTS-P Total), and for therapists regarding the each session (GTS-T). GTS-P Session scores from 0 to 24 with higher values indicating higher acceptance. GTS-P Total scores from 0 to 8 with higher values indicating higher acceptance. GTS-T scores from 0 to 48 with higher values indicating higher acceptance.

    Time frame: GTS-P Session and GTS-T during the intervention (weekly, after each session), GTS-P Total post-intervention

08

Study locations

1 of 1 sites recruiting
  • Neuropsychologische Hochschulambulanz Bielefeld
    Bielefeld, 33602, Germany
    Recruiting
09

References and documents

Publications

  • Hill G, Hynd N, Price J, Evans S, Moffitt J, Brechin D. Living Well with Neurological Conditions: An eight-week series of group workshops informed by Acceptance and Commitment Therapy (ACT); 2017. Available from: URL: https://goo.gl/aX6qB5.
  • Bowers H, Hill G, Webster A, Bowman AR. Living well with neurological conditions: Clinical outcomes, insights and reflections on three years of Acceptance and Commitment Therapy group intervention. The Neuropsychologist 2021; 1(12):33-42.

Individual participant data

Plan to share: Yes — IPD will be shared on public repository like Mendeley Data, while ensuring that no individual may be identified by the data.

Time frame: IPD will be available latest six months after completion of data collection, presumably January, 1st, 2027. Data will be deleted after ten years.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Aug 2026, 20 months after the start.

Of 285 non-industry interventional studies with no phase under Brain Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 20 months is below that.

Counting every sponsor, half of 298 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 27, 2025
StartActual
Dec 1, 2024
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06897553
Lead sponsor
Bielefeld University
Responsible party
Simon Ladwig (Research Fellow (Post-Doc), Bielefeld University) — Principal investigator
First posted
Mar 27, 2025
Start date
Dec 1, 2024
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 27, 2025

Study contacts

Simon Ladwig, PhD
Contact
simon.ladwig@uni-bielefeld.de
+49 (0) 521 106 67533
Franziska Supe, M.Sc.
Contact
franziska-marie.supe@uni-bielefeld.de
+49 (0) 521 106 67533
Katja Werheid, Prof
study chair · Bielefeld University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion